These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Proteus mirabilis - analysis of a concealed source of carbapenemases and development of a diagnostic algorithm for detection. Hamprecht A; Sattler J; Noster J; Stelzer Y; Fuchs F; Dorth V; Gatermann SG; Göttig S Clin Microbiol Infect; 2023 Sep; 29(9):1198.e1-1198.e6. PubMed ID: 37271195 [TBL] [Abstract][Full Text] [Related]
3. Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community. Potron A; Hocquet D; Triponney P; Plésiat P; Bertrand X; Valot B Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962345 [TBL] [Abstract][Full Text] [Related]
4. OXA-48-like carbapenemases in Sattler J; Noster J; Stelzer Y; Spille M; Schäfer S; Xanthopoulou K; Sommer J; Jantsch J; Peter S; Göttig S; Gatermann SG; Hamprecht A Emerg Microbes Infect; 2024 Dec; 13(1):2353310. PubMed ID: 38712879 [TBL] [Abstract][Full Text] [Related]
5. Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis. Bonnet R; Marchandin H; Chanal C; Sirot D; Labia R; De Champs C; Jumas-Bilak E; Sirot J Antimicrob Agents Chemother; 2002 Jun; 46(6):2004-6. PubMed ID: 12019126 [TBL] [Abstract][Full Text] [Related]
6. Inhibitor-resistant TEM- and OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates. Oteo J; González-López JJ; Ortega A; Quintero-Zárate JN; Bou G; Cercenado E; Conejo MC; Martínez-Martínez L; Navarro F; Oliver A; Bartolomé RM; Campos J; Antimicrob Agents Chemother; 2014 Jul; 58(7):3874-81. PubMed ID: 24777096 [TBL] [Abstract][Full Text] [Related]
7. The spread of bla OXA-48 and bla OXA-244 carbapenemase genes among Klebsiella pneumoniae, Proteus mirabilis and Enterobacter spp. isolated in Moscow, Russia. Fursova NK; Astashkin EI; Knyazeva AI; Kartsev NN; Leonova ES; Ershova ON; Alexandrova IA; Kurdyumova NV; Sazikina SY; Volozhantsev NV; Svetoch EA; Dyatlov IA Ann Clin Microbiol Antimicrob; 2015 Nov; 14():46. PubMed ID: 26526183 [TBL] [Abstract][Full Text] [Related]
8. Dissemination of blaOXA-58 in Proteus mirabilis isolates from Germany. Lange F; Pfennigwerth N; Gerigk S; Gohlke F; Oberdorfer K; Purr I; Wohanka N; Roggenkamp A; Gatermann SG; Kaase M J Antimicrob Chemother; 2017 May; 72(5):1334-1339. PubMed ID: 28093482 [TBL] [Abstract][Full Text] [Related]
9. First report of bla Leulmi Z; Kandouli C; Mihoubi I; Benlabed K; Lezzar A; Rolain JM J Glob Antimicrob Resist; 2019 Mar; 16():125-129. PubMed ID: 30217548 [TBL] [Abstract][Full Text] [Related]
10. Chromosomal Amplification of the blaOXA-58 Carbapenemase Gene in a Proteus mirabilis Clinical Isolate. Girlich D; Bonnin RA; Bogaerts P; De Laveleye M; Huang DT; Dortet L; Glaser P; Glupczynski Y; Naas T Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855079 [TBL] [Abstract][Full Text] [Related]
11. Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital. Protonotariou E; Poulou A; Politi L; Meletis G; Chatzopoulou F; Malousi A; Metallidis S; Tsakris A; Skoura L Int J Antimicrob Agents; 2020 Aug; 56(2):106060. PubMed ID: 32574790 [TBL] [Abstract][Full Text] [Related]
12. A single Proteus mirabilis lineage from human and animal sources: a hidden reservoir of OXA-23 or OXA-58 carbapenemases in Enterobacterales. Bonnin RA; Girlich D; Jousset AB; Gauthier L; Cuzon G; Bogaerts P; Haenni M; Madec JY; Couvé-Deacon E; Barraud O; Fortineau N; Glaser P; Glupczynski Y; Dortet L; Naas T Sci Rep; 2020 Jun; 10(1):9160. PubMed ID: 32514057 [TBL] [Abstract][Full Text] [Related]
13. First report of an OXA-48-producing multidrug-resistant Proteus mirabilis strain from Gaza, Palestine. Chen L; Al Laham N; Chavda KD; Mediavilla JR; Jacobs MR; Bonomo RA; Kreiswirth BN Antimicrob Agents Chemother; 2015 Jul; 59(7):4305-7. PubMed ID: 25896692 [TBL] [Abstract][Full Text] [Related]
14. Catalytic and structural properties of IRT-21 beta-lactamase (TEM-77) from a co-amoxiclav-resistant Proteus mirabilis isolate. Mammeri H; Gilly L; Laurans G; Vedel G; Eb F; Paul G FEMS Microbiol Lett; 2001 Dec; 205(2):185-9. PubMed ID: 11750800 [TBL] [Abstract][Full Text] [Related]
15. Identification of AbaR4 Acinetobacter baumannii resistance island in clinical isolates of blaOXA-23-positive Proteus mirabilis. Octavia S; Xu W; Ng OT; Marimuthu K; Venkatachalam I; Cheng B; Lin RTP; Teo JWP J Antimicrob Chemother; 2020 Mar; 75(3):521-525. PubMed ID: 31725155 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Gatermann S; Marre R Infection; 1991; 19(2):106-9. PubMed ID: 1646771 [TBL] [Abstract][Full Text] [Related]
17. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria. Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091 [TBL] [Abstract][Full Text] [Related]
18. Occurrence of NDM-1-producing Morganella morganii and Proteus mirabilis in a single patient in Portugal: probable in vivo transfer by conjugation. Aires-de-Sousa M; Ortiz de la Rosa JM; Goncalves ML; Costa A; Nordmann P; Poirel L J Antimicrob Chemother; 2020 Apr; 75(4):903-906. PubMed ID: 31971235 [TBL] [Abstract][Full Text] [Related]
19. Effect of cloned inhibitor-resistant TEM beta-lactamases on the susceptibility of Haemophilus influenzae to amoxicillin/clavulanate. Tristram SG; Burdach JG J Antimicrob Chemother; 2007 Nov; 60(5):1151-4. PubMed ID: 17827143 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Susceptibility and Molecular Epidemiology of Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]